Skip to main content
Clinical Trials/CTRI/2017/08/009582
CTRI/2017/08/009582
Completed
Phase 4

A randomised, double blind, comparative clinical trial assessing the effectiveness and safety of dapsone 5% versus clindamycin 1% in the treatment of mild to moderate acne vulgaris - DCRCT

Medical College Kolkata0 sites51 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Medical College Kolkata
Enrollment
51
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 27, 2017
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects of 12 to 40 years of age of either sex
  • 2\.Mild to moderate acne: \>\= 2 but \<\= 30 total lesions \- inflammatory (papules and pustules) and/or non\-inflammatory (open and closed comedones)
  • 3\.Lesions in the face which correspond to a baseline investigator global assessment (IGA) score of 2 or 3

Exclusion Criteria

  • 1\.Age \<12 or \>40
  • 2\.Total lesion count \< 2 or \>30,
  • 3\.Subjects regularly using any anti\-acne medications in the last 30 days before study entry
  • 4\.Severe acne: Subjects with nodulo\-cystic lesions, acne conglobata, acne fulminans
  • 5\.Pregnancy or intention of pregnancy and breastfeeding
  • 6\.Patients with G6PD deficiency
  • 7\.History of having taken any medication that could interact with dapsone (e.g. Trimetoprim\-sulfametoxazol
  • 8\.Known hypersensitivity to the study medication
  • 9\.Patients not willing to comply with protocol requirements

Outcomes

Primary Outcomes

Not specified

Similar Trials